# Psilocybin for Smoking Cessation: 80% Quit Rate Study Explained
For many, the battle against nicotine addiction is a lifelong struggle. Despite numerous conventional treatments, a significant number of individuals find themselves caught in a cycle of quitting and relapsing. But what if there was a different path, one that offered a remarkably high success rate?
Emerging research, particularly a groundbreaking study from Johns Hopkins University, suggests that psilocybin – the psychedelic compound found in magic mushrooms – could be a powerful ally in the fight against smoking addiction. This research has reported an astonishing 80% quit rate, offering a beacon of hope for those who have exhausted other options.
Addiction: With Mushroom Support vs. Without
| Metric |
Without Mushroom Support |
With Mushroom Support (Lion's Mane + Psilocybin) |
| Sleep Quality |
Severely disrupted; withdrawal and cravings interrupt sleep |
Improved sleep quality; reduced craving-driven nighttime arousal |
| Emotional Range |
Emotional dysregulation; substance used to manage feelings |
Greater emotional processing capacity without substance reliance |
| Energy Levels |
Cycles of stimulation and crash; chronic fatigue in recovery |
More stable energy as neurochemistry normalizes |
| Anxiety / Rumination |
Anxiety drives craving; craving drives use in a vicious cycle |
Reduced craving intensity; psilocybin interrupts the addiction loop |
| Sense of Connection |
Isolation; relationships damaged by addiction |
Increased sense of connection reduces the pull of substance use |
| Cognitive Clarity |
Impaired by substance use and withdrawal fog |
Cognitive recovery supported by Lion's Mane neurogenesis |
| Motivation & Drive |
Motivation hijacked by addiction; only substance matters |
Reconnection with values and long-term goals |
| Time to Noticeable Change |
Addiction is chronic and relapsing without sustained support |
Johns Hopkins smoking study: 80% abstinence at 6 months after 2–3 psilocybin sessions |
Sources: Johns Hopkins Medicine, Imperial College London, NEJM 2021 psilocybin trial, Mori et al. 2009 (Lion's Mane), Stamets 2019 (microdosing survey)
## The Johns Hopkins Study: A Closer Look at the 80% Success Rate
Published in the *Journal of Psychopharmacology* in 2014, the Johns Hopkins study, led by Dr. Matthew W. Johnson, investigated the efficacy of psilocybin-assisted therapy for smoking cessation. The study involved 15 participants who had smoked an average of 19 cigarettes per day for 31 years and had made multiple failed attempts to quit.
Participants underwent a carefully structured program that combined cognitive behavioral therapy (CBT) with psilocybin administration. This wasn't simply about taking a pill; it was a comprehensive therapeutic process. Participants received two to three doses of psilocybin over several weeks, carefully monitored by trained therapists. The psilocybin sessions were designed to be profound, introspective experiences, allowing participants to explore the roots of their addiction and reframe their relationship with smoking.
### Key Findings and Why They Matter
The results were remarkable: 80% of participants achieved abstinence from smoking at a 6-month follow-up. This success rate significantly surpasses that of most conventional smoking cessation treatments, which typically range from 10% to 30% for behavioral therapies and pharmacotherapies like nicotine replacement or bupropion (JAMA, 2013). At a 12-month follow-up, 67% of participants remained abstinent, and at a 16-month follow-up, 60% were still smoke-free, demonstrating impressive long-term efficacy.
This study provided compelling preliminary evidence that psilocybin, when administered in a therapeutic context, can be a highly effective treatment for nicotine addiction. It highlighted the potential of psychedelics to facilitate deep psychological insights and behavioral change that traditional methods often struggle to achieve.
## How Does Psilocybin Help You Quit Smoking?
The mechanism by which psilocybin aids in smoking cessation is multifaceted and still being fully understood, but current theories point to several key factors:
### 1. Disrupting Habitual Patterns and Creating New Perspectives
Nicotine addiction is deeply ingrained, both physiologically and psychologically. Psilocybin is believed to temporarily disrupt rigid thought patterns and neural pathways associated with addiction. During a psilocybin experience, individuals often report a sense of interconnectedness, a shift in perspective, and a greater awareness of their behaviors and motivations. This can allow them to see their smoking habit not as an inherent part of their identity, but as an external behavior they can change.
### 2. Enhancing Emotional Processing and Insight
Many addictions are linked to underlying emotional distress, trauma, or coping mechanisms. Psilocybin can facilitate access to repressed emotions and memories, allowing individuals to process them in a safe, therapeutic setting. This emotional release and insight can address the root causes of addiction, making it easier to break free from the reliance on substances like nicotine.
### 3. Increasing Openness and Suggestibility
Research suggests that psilocybin can increase a person's psychological flexibility and openness to new ideas and behaviors (Imperial College London, 2018). This enhanced suggestibility, when guided by a skilled therapist, can make individuals more receptive to therapeutic interventions and more willing to embrace a smoke-free life.
## The Role of Therapeutic Support
It's crucial to understand that the success of psilocybin for smoking cessation, or any addiction, is not solely due to the compound itself. The therapeutic framework is paramount. The Johns Hopkins study, and subsequent research, emphasizes the importance of:
* **Preparation Sessions:** Helping participants set intentions, understand the process, and build trust with their therapists.
* **Guided Psilocybin Sessions:** Providing a safe, supportive environment during the psychedelic experience, with therapists present to offer guidance and reassurance.
* **Integration Sessions:** Helping participants process their experiences, integrate insights into their daily lives, and develop coping strategies for maintaining abstinence.
This comprehensive approach is what differentiates responsible, research-backed psilocybin-assisted therapy from recreational use.
## Beyond Smoking: Psilocybin's Potential for Other Addictions
The promising results from smoking cessation research have spurred interest in psilocybin's potential for treating other substance use disorders, including alcohol dependence and opioid addiction. Early studies and ongoing trials are exploring similar therapeutic models, with initial findings suggesting broad applicability for psilocybin in addiction treatment (NYU, 2016).
For those seeking alternatives to traditional methods, exploring the potential of psilocybin-assisted therapy opens up new avenues. Brands like Shrooomz are dedicated to providing high-quality psilocybin products for responsible adult use in jurisdictions where it is legal. For those looking for a gentle, consistent approach to well-being, options like **Happy Shrooomz** (150mg psilocybin + ginger) could be considered as part of a holistic wellness journey, always remembering that therapeutic protocols are key for addiction treatment.
## The Bottom Line
The Johns Hopkins study on psilocybin for smoking cessation offers compelling evidence for a powerful new approach to nicotine addiction. An 80% quit rate is not just a statistic; it represents a significant shift in how we might view and treat deeply entrenched habits. While more large-scale research is needed, the current findings provide substantial hope. Psilocybin, when combined with expert therapeutic guidance, appears to offer a unique pathway to breaking free from addiction by fostering profound psychological shifts and renewed perspectives.
If you or someone you know is struggling with nicotine addiction and has found conventional methods falling short, keeping an eye on the evolving landscape of psychedelic-assisted therapy could be life-changing. Learn more about responsible psilocybin use and its potential at shrooomz.com.
**References:**
* Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology, 28*(11), 983-992.
* Fiore, M. C., Jaén, C. R., Baker, T. B., et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. U.S. Department of Health and Human Services. (Referenced for conventional quit rates, often cited by JAMA reviews).
* Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. *Neuropsychopharmacology, 42*(11), 2101-2115. (Referenced for general mechanisms of action, Imperial College London research).
* Bogenschutz, M. P., Forcehimes, A. A., Pomara, J. A., et al. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. *Journal of Psychopharmacology, 29*(3), 280-289. (NYU research on alcohol dependence).
Research Hub
Psilocybin & Microdosing Research Hub
Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.
Browse the Research Hub →